2020 ASCO Virtual Scientific Meeting*

Download All
May 29-31, 2020; Online at meetings.asco.org/am
Review slidesets and expert analyses of key data from the 2020 Clinical Oncology Virtual Scientific Meeting!

Genitourinary Cancers

Capsule Summary Slidesets

ARV-110, a proteolysis-targeting chimera, shows promising clinical activity in heavily pretreated mCRPC patients who have received at least 1 second-generation AR therapy.

Released: June 8, 2020

Adjuvant atezolizumab did not improve disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma compared with observation.

Released: June 8, 2020

After nearly 2 years of follow-up, pembrolizumab plus axitinib provides durable improvements in OS and PFS as compared with sunitinib in treatment-naive patients with advanced RCC.

Released: June 2, 2020

Savolitinib demonstrated promising improvements in PFS, OS, and response rate with favorable safety outcomes vs sunitinib.

Released: June 1, 2020

A subset of patients with advanced RCC previously treated with checkpoint inhibitors responded to subsequent treatment with nivolumab + ipilimumab.

Released: June 1, 2020

Biomarker evaluation suggests that prolonged PFS with nivo plus ipi may be associated with enhanced expression of genes involved in the tumor microenvironment and inflammatory responses; PD-L1 expression is not predictive for OS or PFS.

Released: June 3, 2020

PBRM1 mutations and del(9p21.3) associated with outcomes in advanced clear cell RCC treated with immune checkpoint inhibitors.

Released: June 8, 2020

Cabozantinib plus atezolizumab resulted in durable tumor responses with tolerable toxicity in patients with urothelial carcinoma previously treated with platinum-based chemotherapy.

Released: June 1, 2020

Combination enfortumab vedotin plus pembrolizumab demonstrated rapid, durable response, regardless of PD-L1 status, in untreated, cisplatin-ineligible patients with advanced urothelial carcinoma.

Released: June 5, 2020

Use of antibiotics 30 days before or after starting ICI therapy in patients with advanced urothelial cancer associated with worse survival outcomes in this retrospective, exploratory analysis.

Released: June 5, 2020

Darolutamide plus ADT led to 31% risk reduction of death vs placebo plus ADT and no new safety concerns upon longer follow-up.

Released: June 4, 2020

Maintenance avelumab plus BSC significantly prolonged OS in the overall population and in patients with PD-L1–positive disease.

Released: June 3, 2020
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Pfizer, Inc. and EMD Serono

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings